PM 1130
Alternative Names: PM-1130Latest Information Update: 05 Feb 2024
At a glance
- Originator Biotheus
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action CD40 antigen stimulants; Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 20 Dec 2023 Preclinical trials in Solid tumours in China (unspecified route), prior to December 2023 (Biotheus pipeline, December 2023)